Philadelphia, PA – June 19, 2015
On June 17th, the CEO of Mocuis Co., Ltd, Seungyun “Jenny” Jo (조승연), served on a panel to discuss bringing drugs from South Korea, China, and emerging markets, to higher regulated markets, such as the US and EU. The panel offered insights in improving the process from drug discovery to global commercialization. Topics included process efficiency, regulatory hurdles, partnership, funding, and licensing.
Joining Ms. Jo, was Blake Salisbury, Senior Director Corporate Business Development Emerging Markets Business Unit at Eli Lilly, Anthony Abruzzini, Vice President Global Strategic Drug Development at Quintiles, and moderator Richard Brown, General Partner at Plexus Ventures.
The Bio International Convention 2015 is the largest global event for the biotech industry and many of the biggest names in biotech and pharmaceuticals are in attendance. Over 15,000 attendees convened in Philadelphia, PA USA for this year’s event. Bio International Convention features over 3,100 companies from over 70 countries.
The speaker panel also presented Radotinib HCl (Supect®) as a case study in bringing a novel drug from South Korea to the US and EU. Supect® was developed by Ilyang Pharmaceutical in South Korea for the treatment of Chronic Myeloid Leukemia. It is the first Asian developed drug for treating leukemia.
Ms Jo said, “It is an exciting time for drug development in the emerging markets. We are seeing many great partnerships between Korean companies and multi-national pharmaceutical companies. With the commitment from the South Korean government’s Pharma 2020 Vision, expect Korea to continue driving innovation and global growth.”
About Mocuis Co., Ltd
Mocuis (모크스), is a specialty firm that advises and invests with partners in a tailored approach to maximize asset and stakeholder value. Mocuis focuses on quality businesses with leading positions in areas such as, biotech, pharmaceutical, and technology. With headquarters in Seoul and a satellite office in Chicago, Mocuis has key locations to build better international businesses through strategic partnerships, professional practices, effective capital, and global capabilities.